The Paroxysmal Nocturnal Hemoglobinuria drugs in development market research report provides comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Paroxysmal Nocturnal Hemoglobinuria. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and features dormant and discontinued products.

GlobalData tracks 44 drugs in development for Paroxysmal Nocturnal Hemoglobinuria by 34 companies/universities/institutes. The top development phase for Paroxysmal Nocturnal Hemoglobinuria is preclinical with 16 drugs in that stage. The Paroxysmal Nocturnal Hemoglobinuria pipeline has 44 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Paroxysmal Nocturnal Hemoglobinuria pipeline products market are: Alexion Pharmaceuticals, NovelMed Therapeutics and Novartis.

The key targets in the Paroxysmal Nocturnal Hemoglobinuria pipeline products market include Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5), Complement Factor D (C3 Convertase Activator or Adipsin or Properdin Factor D or CFD or EC 3.4.21.46), and Complement Factor B (Glycine Rich Beta Glycoprotein or C3/C5 Convertase or Properdin Factor B or PBF2 or CFB or EC 3.4.21.47).

The key mechanisms of action in the Paroxysmal Nocturnal Hemoglobinuria pipeline product include Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Inhibitor with 18 drugs in Pre-Registration. The Paroxysmal Nocturnal Hemoglobinuria pipeline products include six routes of administration with the top ROA being Intravenous and seven key molecule types in the Paroxysmal Nocturnal Hemoglobinuria pipeline products market including Monoclonal Antibody, and Small Molecule.

Paroxysmal Nocturnal Hemoglobinuria overview

Paroxysmal nocturnal hemoglobinuria is a rare disease in which red blood cells break down earlier than normal. Symptoms include abdominal pain, back pain, dark urine, easy bruising or bleeding, headache, and shortness of breath. The predisposing factors include age, obesity, and hormone therapy. Treatment includes surgery, chemotherapy, and radiation therapy.

For a complete picture of Paroxysmal Nocturnal Hemoglobinuria’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.